Time to retreatment after abobotulinumtoxinA (Dysport[®]) injections in children with dynamic equinus foot deformity

Nigar Dursun,¹ Jorge Carranza,² Ann Tilton,³ Resa Aydin,⁴ Ece Unlu,⁵ Belgin Erhan,⁶ Maria Luisa Rodriguez,⁷ Philippe Picaut,⁷ Anne-Sophie Grandoulier,⁷ Mauricio R. Delgado.⁸ ¹Kocaeli University Medical Faculty, Izmit, Turkey; ²Hospital San José Celaya, Celaya, Guanajuato, Mexico; ³Louisiana State University Health Center and Children's Hospital New Orleans, New Orleans, Louisiana, USA; ⁴Istanbul Medical School, Istanbul, Turkey; ⁴ ⁵Yildirim Beyazit Training and Research Hospital, Ankara, Turkey; ⁷Ipsen Pharma, Les Ulis, France; ⁸Texas Scottish Rite Hospital for Children, Dallas, Texas, USA

Introduction

- Evidence-based clinical guidelines consistently recommend botulinum neurotoxin type A (BoNT-A) as an effective and generally safe and well tolerated treatment for localised/segmental spasticity in children and adolescents with cerebral palsy (CP).^{1, 2} However, the effects of chemodenervation with BoNT-A are transient, and repeat injections are often necessary to achieve and maintain clinical benefit.
- The minimum interval between BoNT-A injections is currently mandated by regulatory authorities to be 12 weeks, which, for a child undergoing regular repeated BoNT-A treatment, could mean as many as 4 injection appointments per year.
- While there is little published data on the caregiver burden associated with attending frequent healthcare visits, the multimodal approach to managing CP often necessitates several appointments with various healthcare professionals per year. From the patient/ caregiver perspective, the time required for a BoNT-A injection can be particularly substantial; for each injection visit, the child will likely miss a day from nursery/school, and the parental guardian must make the necessary arrangements (e.g. time off work, travel arrangements) to accompany their child. The emotional burden of undergoing an injection procedure, especially as this may require sedation, should also be considered. Thus, a longer injection interval is of interest to this patient population.
- From the economic perspective, longer time to retreatment is of interest as a way to reduce costs. Direct medical costs include the cost of toxin and associated clinic costs (e.g. staffing, use of injection guidance technique, day bed allocation), which can significantly increase with sedation/anaesthesia.³

- We have previously reported the primary efficacy results of a large, international, randomised, placebo-controlled Phase 3 study which demonstrated superiority of abobotulinumtoxinA versus placebo in improving hypertonia (MAS) and spasticity (Tardieu), Function (Physician Global Assessment) and attainment of treatment goals (Goal attainment scaling).4, 5
- This study permitted flexible injection intervals based on specific re-treatment criteria. The aim of this analysis was to describe the time to retreatment for patients having received active treatment in the double-blind phase of the study.

Methods

Study design⁴

- This was a Phase 3, international, multicentre, double-blind, prospective, randomised, placebo-controlled, singledose study (NCT01249417; Figure 1).
- All patients who successfully completed the double-blind study and who continued to meet eligibility criteria (Table 1) could enter the open-label phase of the study (NCT01251380; Figure 1).
- During the double-blind study, patients received injections of placebo, 10 U/ kg/leg abobotulinumtoxinA (i.e. 20 U/ kg for bilateral injections) or 15 U/kg/ leg abobotulinumtoxinA (i.e. 30 U/kg for bilateral injections) into the gastrocnemius and soleus muscles. The maximum total dose was 30 U/kg or 1000 U, whichever the lower value.
- Following treatment administration, patients attended follow-up visits at Week 4 and Week 12. Additional visits to evaluate eligibility criteria for retreatment were permitted at Week 16 (for patients who in the clinical judgment of the

investigator did not require retreatment at Week 12), at Week 22 (patients who did not require retreatment at Week 16) and at Week 28 (patients who did not require retreatment at Week 22).

- If assessed as eligible for retreatment, patients were then included in the openlabel study.
- Eligibility for retreatment was defined as follows:
- 1. If the patient has not demonstrated a decrease from baseline of ≥1 grade in the MAS score in the gastrocnemiussoleus complex at the ankle joint and has no improvement on the PGA (i.e. score \leq o), and if based on the investigator's judgement there is no unacceptable safety risk

- 2. If the patient has demonstrated a decrease from baseline of ≥ 1 grade in the MAS score in the gastrocnemius-soleus complex at the ankle joint and/or has demonstrated an improvement on the PGA (i.e. a score \geq +1), the Investigator will decide based on the other efficacy and safety assessments whether the patient needs to be injected on the same day or whether the injection is postponed to the next scheduled visit (i.e. Week 16, 22, 28 or later).
- The minimum retreatment interval was 12 weeks.

Results

Time to retreatment

• Overall, 158 patients received abobotulinumtoxinA (10U/Kg/leg or 15U/ kg/leg) in the double-blind study and 134 entered the open-label phase. Table 2 provides a breakdown of the doubleblind visits at which patients in each active treatment group met retreatment criteria.

Table 1. Key eligibility criteria⁴

- Ambulatory children (aged 2–17 years) with a diagnosis of spasticity due to CP and equinus foot positioning during the stance phase of the gait
- Gross Motor Function Classification System (GMFCS) Level of I-III
- Modified Ashworth Scale (MAS) ≥ 2 and a spasticity grade (Y) of 2-4 on the Tardieu scale (with a spasticity angle (X) of 10° or more) at the ankle joint
- No fixed ankle flexion myocontractures, previous surgery, or alcohol/phenol injections
- No serial casting in the past 12 weeks
- BoNT naïve or a minimum of 6 months' washout from the last BoNT injection for any condition


Table 3: Treatment related adverse events in double-blind phase (occurring \geq 2 patients)

AboBoNT-A 10 U/kg/leg (N=80)	AboBoNT-A 15 U/kg/leg (N=80)	Combined doses (N=160)
6 (7.5)	5 (6.3)	11 (6.9)
2 (2.5)	0	2 (1.3)
1 (1.3)	1 (1.3)	2 (1.3)
1 (1.3)	Ο	1 (0.6)
	6 (7.5) 2 (2.5) 1 (1.3)	6 (7.5) $5 (6.3)$ $2 (2.5)$ 0 $1 (1.3)$ $1 (1.3)$

- The majority (74%) of abobotulinumtoxinA treated patients did not require retreatment for ≥ 16 weeks; of these, 17.7% did not meet eligibility criteria until week 28 or later (Figure 4).
- Figure 3 shows the proportion of MAS responders in each active treatment group at each visit during the double-blind phase.
- This reduction in muscle tone was reflected in the Physicians Global Assessment (PGA) of treatment response at every visit (Figure 3).


Safety


• The incidence of treatment-related TEAEs was low; the only treatment-related TEAE reported by more than 2% of abobotulinumtoxinA-treated subjects were local muscular weakness and injection site pain (Table 3).




Conclusions

- In this study, 74% of patients had a time to retreatment much longer than the 'standard' 12 weeks, following abobotulinumtoxinA injection
- 18% patients did not require reinjection for at least 28 weeks after abobotulinumtoxinA injection
- These data highlight the need to determine the time to retreatment on an individual basis
- At the 2 dose levels the retreatment interval was comparable and exceeded the standard 12 weeks
- In children with CP receiving regular BoNT-A treatments, extending the interval from 12 weeks to 16 weeks would mean one less injection per year.







Scan here to view a PDF of this poster Copies of this poster obtained through Quick **Response Code are for** personal use only

QR code to be provided by Toxins

Week 28 79 69 42 31 19 79 74 47 30 14

investigators and patients involved in the studies and Anita Chadha-Patel (ACP Clir Communications Ltd) for writing assista (funded by Ipsen).

References

1. Delgado MR, Hirtz D, Aisen M, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2010;74(4):336-343; 2. NICE. Guideline CG145. Spasticity in children and young people with non-progressive brain disorders: Management of spasticity and coexisting motor disorders and their early musculoskeletal complications. 2012; 3. NICE. Spasticity in children and young people with non-progressive brain disorders. Costing report - Implementing NICE guidance. Available at https://www.nice.org.uk/guidance/cg145/resources/costing-report-186767821. 2012; 4. Delgado MR, Tilton A, Russman B, et al. AbobotulinumtoxinA for Equinus Foot Deformity in Cerebral Palsy: A Randomized Controlled Trial. Pediatrics 2016;137(2):1-9; 5. Tilton A et al. Journal of Child Neurology. 2017 Jan 1:883073816686910.

institutions have received payment for participation

No author has received financial remuneration for the

preparation of this abstract or poster.